Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P4, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

P3, N=700, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting

P3, N=312, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P1, N=33, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Jun 2027

A higher regression rate than expected was observed in the surveillance arm of this prospective trial. Future clinical trials with imiquimod targeting CIN3 patients are warranted.

P=N/A, N=610, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Mar 2024 --> Sep 2024

P4, N=360, Recruiting, Boston Medical Center | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2024 --> Sep 2024

P2/3, N=120, Recruiting, Western Institute for Veterans Research | Not yet recruiting --> Recruiting

P4, N=120, Recruiting, Talia Sainz Costa | Not yet recruiting --> Recruiting

P4, N=757, Active, not recruiting, The University of Texas Medical Branch, Galveston | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Feb 2024 --> Mar 2025

P2, N=52, Active, not recruiting, National Cancer Institute (NCI) | N=180 --> 52 | Trial completion date: Dec 2023 --> Mar 2025

P2, N=201, Active, not recruiting, National Cancer Institute (NCI) | Phase classification: P2a --> P2 | Trial completion date: Feb 2024 --> Feb 2025

P4, N=1403, Active, not recruiting, Columbia University | Trial completion date: Oct 2023 --> Sep 2024

P4, N=100, Recruiting, Medical College of Wisconsin | Phase classification: P=N/A --> P4

P4, N=97, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting

P=N/A, N=610, Not yet recruiting, University of Alabama at Birmingham

P3, N=536, Active, not recruiting, AIDS Malignancy Consortium | Trial primary completion date: Dec 2025 --> Dec 2024

P3, N=1260, Active, not recruiting, Beijing Health Guard Biotechnology, Inc | Recruiting --> Active, not recruiting

P1, N=33, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2025 --> Apr 2026

P3, N=1260, Recruiting, Beijing Health Guard Biotechnology, Inc

P=N/A, N=392, Not yet recruiting, Xiamen Ophthalmology Center Affiliated to Xiamen University

P3, N=536, Active, not recruiting, AIDS Malignancy Consortium | Trial primary completion date: Mar 2025 --> Dec 2025 | Recruiting --> Active, not recruiting

P3, N=165, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P2, N=100, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Feb 2024 --> Dec 2025

P=N/A, N=4453, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2024 --> Jan 2040 | Trial primary completion date: Jan 2024 --> Jan 2040

P4, N=100, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Apr 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P2/3, N=120, Not yet recruiting, Western Institute for Veterans Research | Trial completion date: Dec 2025 --> Dec 2026 | Initiation date: Jun 2023 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2025

Gardasil-9 vaccination showed good efficacy in reducing major dermatologic interventions even after correction of relevant cofactors and national COVID-19 caseloads during the observational period. Alpha-HPV vaccination may potentially cause a significant decrease in dermatologic interventions and overall mortality as well as healthcare costs in immunosuppressed patients with high skin tumor burden.

Opportunistic vaccination offers the possibility of including individuals excluded from the free vaccination campaigns, often already affected by lesions caused by HPV, providing increased viral clearance and faster lesion regression. The main limit remains the economic burden.

There are discrepancies around gynaecological cancer screenings provision among EBCOG member countries. It is important to establish European recommendations about screening for gynaecological cancers, in order to standardize the access to equitable better health care in gynaecological cancers within Europe.

Oral HPV prevalence was 6.6% (95% CI, 5.7%-7.4%) for any HPV genotype, and 2.0% (95% CI, 1.5%-2.5%), 0.7% (95% CI, 0.4%-1.0%), and 1.5% (95% CI, 1.1%-1.9%) for HR, HPV-16, and 9-valent-HPV vaccine types, respectively...In this cross-sectional study, oral HPV burden was highest among older men who may be at higher risk of developing oropharyngeal cancer. In addition to male sex and older age, HR oral HPV infection was also associated with sexual behaviors, including increasing number of male sex partners and female oral sex partners.

Prophylactic vaccines against high-risk human papillomaviruses (HR-HPVs) hold promise to prevent the development of higher grade cervical intraepithelial neoplasia (CIN 2+) and cervical cancer (CC) that develop due to HR-HPV genotypes that are included, in HPV vaccines, but women will continue to develop CIN 2+ and CC due to HR-HPV genotypes that are not included in the quadrivalent HPV vaccine (qHPV) and 9-valent HPV vaccine (9VHPV)...We identified vitamin B12 status and smoking as independent modifiable factors and ethnicity as a factor that needs attention to reduce the risk of developing CIN 2+ in the post vaccination era. Continuation of tailored screening programs combined with non-vaccine-based approaches are needed to manage the residual risk of developing HPV-related CIN 2+ and CC in vaccinated women.

Adjuvant HPV vaccination in the setting of surgical treatment for cervical precancerous lesion is significantly associated with a reduced risk of recurrence. HPV vaccination should be strongly considered as adjuvant therapy, especially in young patients undergoing conisation for a severe cervical lesion.

To our knowledge, this is the first documented case report of 9vHPV-associated MG in China. Although ocular MG may be a rare adverse event after vaccination with 9vHPV, there is currently no direct evidence establishing a causal relationship; therefore, the safety of 9vHPV remains unquestioned.

Additionally, in July 2020, the Japanese government approved the updated 9-valent HPV vaccine and resumed recommendations in November 2021. As a result, 30.1% of those eligible for routine HPV vaccination received at least one dose of the vaccine from April to September, 2022. However, the HPV vaccine coverage in Japan is still far from the 90% recommended by the World Health Organization, and continued communication and education on the vaccines benefits are necessary to achieve optimal coverage.

Results were consistent across the three independent models and suggest that one-dose vaccination has similar health benefits to a two-dose programme while simplifying vaccine delivery, reducing costs, and alleviating vaccine supply constraints. The second dose may become cost-effective if there is a shorter duration of protection from one dose, cheaper vaccine and vaccination delivery strategies, and high burden of cervical cancer.

Regardless of actual vaccination status, respondents mostly preferred the 9-valent HPV vaccine (58.6%), followed by 4-valent (15.6%) and 2-valent vaccines (3.1%); additionally, 17.9% did not have a preference...In conclusion, HPV vaccine uptake is high in Chinese female health care workers. HBM constructs may be effective in facilitating the improvement and delivery of targeted intervention programs to increase HPV vaccine uptake.

Cecolin 9 induced non-inferior HPV type-specific immune responses compared with Gardasil 9 and is a potential candidate to accelerate the elimination of cervical cancer by allowing for global accessibility to 9-valent HPV vaccinations, especially in low-income and middle-income countries.

Cervical HR-HPV infection is particularly frequent in young or HIV-infected Congolese women. Prophylactic HPV vaccination combined with primary molecular screening of HR-HPV infection in this country should be extended.

Extended HPV genotyping had good agreement with a well-validated partial HPV genotyping CC primary screening kit in hr-HPV detection. Extended HPV genotyping could facilitate risk-based stratified management strategy and improve the diagnostic accuracy of primary CC screening.

P4, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024

In contrast, oral HPV infections were significantly associated with women aged 36 to 50 years (OR 27.38, 95% CI: 4.37-171.37; p = 0.000202) and oral sex (OR 95.5, 95% CI: 5.13-1782.75, p = 0.001126).Additionally, being separate, being cohabitant, lifetime sexual partners of >10, 3-5 lifetime sexual partners, 10 sexual intercourse per month, occasional and regular anal sex, >20 cigarettes per day, a history of sexually transmitted disease (herpes and multiple), and having a history of genital warts were significant. Screening and early diagnosis are considered to be practically unfeasible for this category of cancer, given the lack of visible lesions; the 9-valent HPV vaccine remains the only means that could help to successfully counter the growing incidence of oral squamous cell carcinoma.